642 related articles for article (PubMed ID: 18399120)
1. [Influence of overexpressed coagulant and fibrolytic components in tumor tissues on the prognosis of non-small cell lung cancer].
Chen WH; Wang C; Zhang YH; Yang YH; Zhan HY; Zhang LM
Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(45):3228-32. PubMed ID: 18399120
[TBL] [Abstract][Full Text] [Related]
2. [Expression and clinical significance of coagulate and fibrolysis factors in tissue and plasma from hepatocellular carcinoma patients].
Zhou Q; Liang LJ; Peng BG; Zhen YY
Ai Zheng; 2006 Nov; 25(11):1433-8. PubMed ID: 17094916
[TBL] [Abstract][Full Text] [Related]
3. Cathepsin B, plasminogenactivator-inhibitor (PAI-1) and plasminogenactivator-receptor (uPAR) are prognostic factors for patients with non-small cell lung cancer.
Werle B; Kotzsch M; Lah TT; Kos J; Gabrijelcic-Geiger D; Spiess E; Schirren J; Ebert W; Fiehn W; Luther T; Magdolen V; Schmitt M; Harbeck N
Anticancer Res; 2004; 24(6):4147-61. PubMed ID: 15736466
[TBL] [Abstract][Full Text] [Related]
4. [The expression of urokinase-type plasminogen activator and its receptor in urinary transitional cell carcinoma].
Li YJ; Zheng BZ; Zhou ZL
Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Jan; 35(1):57-9. PubMed ID: 14981816
[TBL] [Abstract][Full Text] [Related]
5. Multimarker phenotype predicts adverse survival in patients with lymph node-negative colorectal cancer.
Zlobec I; Minoo P; Baumhoer D; Baker K; Terracciano L; Jass JR; Lugli A
Cancer; 2008 Feb; 112(3):495-502. PubMed ID: 18076013
[TBL] [Abstract][Full Text] [Related]
6. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
[TBL] [Abstract][Full Text] [Related]
7. Expression of urokinase plasminogen activator and its receptor in advanced epithelial ovarian cancer patients.
Wang L; Madigan MC; Chen H; Liu F; Patterson KI; Beretov J; O'Brien PM; Li Y
Gynecol Oncol; 2009 Aug; 114(2):265-72. PubMed ID: 19450871
[TBL] [Abstract][Full Text] [Related]
8. Changes in plasminogen activator inhibitor-1 levels in non-small cell lung cancer.
Pavey SJ; Marsh NA; Ray MJ; Butler D; Dare AJ; Hawson GA
Boll Soc Ital Biol Sper; 1996; 72(11-12):331-40. PubMed ID: 9178585
[TBL] [Abstract][Full Text] [Related]
9. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H
J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
[TBL] [Abstract][Full Text] [Related]
10. [Expression and significance of the urokinase-type plasminogen activator and its inhibitors in squamous cell carcinoma of human larynx].
Zhao EM; Han DM; Yu ZK; Fan EZ; Li Y
Zhonghua Er Bi Yan Hou Ke Za Zhi; 2003 Feb; 38(1):39-42. PubMed ID: 12778766
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of Pokemon in non-small cell lung cancer and foreshowing tumor biological behavior as well as clinical results.
Zhao ZH; Wang SF; Yu L; Wang J; Chang H; Yan WL; Zhang J; Fu K
Lung Cancer; 2008 Oct; 62(1):113-9. PubMed ID: 18550205
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression.
Sawai H; Okada Y; Funahashi H; Matsuo Y; Takahashi H; Takeyama H; Manabe T
BMC Cell Biol; 2006 Feb; 7():8. PubMed ID: 16504015
[TBL] [Abstract][Full Text] [Related]
13. Expression of nestin in lymph node metastasis and lymphangiogenesis in non-small cell lung cancer patients.
Chen Z; Wang T; Luo H; Lai Y; Yang X; Li F; Lei Y; Su C; Zhang X; Lahn BT; Xiang AP
Hum Pathol; 2010 May; 41(5):737-44. PubMed ID: 20132963
[TBL] [Abstract][Full Text] [Related]
14. [Expression of urokinase-type plasminogen activator and its receptor protein in synovial tissues from osteoarthritis].
Wang WC; Wang Y; Sun CJ
Hunan Yi Ke Da Xue Xue Bao; 2001 Jun; 26(3):257-60. PubMed ID: 12536699
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma.
Xue A; Scarlett CJ; Jackson CJ; Allen BJ; Smith RC
Pancreas; 2008 Mar; 36(2):160-7. PubMed ID: 18376307
[TBL] [Abstract][Full Text] [Related]
16. Tumour cell expression of C4.4A, a structural homologue of the urokinase receptor, correlates with poor prognosis in non-small cell lung cancer.
Hansen LV; Skov BG; Ploug M; Pappot H
Lung Cancer; 2007 Nov; 58(2):260-6. PubMed ID: 17706320
[TBL] [Abstract][Full Text] [Related]
17. [Association of uPA and uPAR expression with invasive behaviors of urinary transitional cell carcinoma].
Li YJ; Zheng BZ; Zhou ZL
Ai Zheng; 2004 Jun; 23(6):704-6. PubMed ID: 15191676
[TBL] [Abstract][Full Text] [Related]
18. Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87).
Krüger A; Soeltl R; Lutz V; Wilhelm OG; Magdolen V; Rojo EE; Hantzopoulos PA; Graeff H; Gänsbacher B; Schmitt M
Cancer Gene Ther; 2000 Feb; 7(2):292-9. PubMed ID: 10770639
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue.
Pedersen H; Brünner N; Francis D; Osterlind K; Rønne E; Hansen HH; Danø K; Grøndahl-Hansen J
Cancer Res; 1994 Sep; 54(17):4671-5. PubMed ID: 8062262
[TBL] [Abstract][Full Text] [Related]
20. Enhanced expression of urokinase receptor induced through the tissue factor-factor VIIa pathway in human pancreatic cancer.
Taniguchi T; Kakkar AK; Tuddenham EG; Williamson RC; Lemoine NR
Cancer Res; 1998 Oct; 58(19):4461-7. PubMed ID: 9766679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
